Abstract library

30 results for "Zappa".
#283 Primary Lymph Node Gastrinoma: A Genuine Entity? Two Case Reports and a Review of the Literature
Introduction: The existence of primary lymph node gastrinoma has been proposed but is controversial. We report two cases (Case A - 37-year-old male, Case B - 43-year-old male) of apparent primary lymph node gastrinoma.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Richard W Carroll
#973 Toward a Preoperative Classification of Mesenteric Lymph Node Metastases for Better Selection of Carcinoid Tumors Before Radical Surgery
Introduction: Surgery for small bowel carcinoid (SBC) and lymph node (LN) metastases, when technically possible, represents the best therapy. However, surgical challenge is (i) not to recuse patients for false unresectable mesenteric artery invasion, and/or (ii) to avoid extensive small bowel resection.
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: MD PhD Reza Kianmanesh
#199 Magnetic Resonance Imaging (MRI) v. Endoscopic Ultrasonography (EUS) for the Detection of =10-mm Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1 (MEN1). A GTE Study
Introduction: In MEN1, the main risk factor of metastases is pancreatic tumor size. We and others recommend limiting surgery to pancreatic tumors >20 mm or growing based on their size measured with EUS.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Guillaume Cadiot
#475 Methylguanine DNA Methyl Transferase (MGMT) Expression Predicts Response to Temozolamide in Patients with Digestive Neuroendocrine Tumors (NETs)
Introduction: Temozolomide (TEM) is an oral drug with encouraging results in pancreatic NETs (PNETs). MGMT tumor deficiency seems to be correlated with higher treatment efficacy.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Olivia Hentic
Authors: Hentic O, Cros J, Rebours V, Zappa M, ...
#745 Surgery after Peptide Receptor Radionuclide Therapy (PRRT) for Patients with Neuroendocrine Tumors (NETs) with Metastatic Abdominal Localizations.
Introduction: There are only few case reports about surgery in patients affected by gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients previously underwent peptide receptor radionuclide therapy (PRRT).
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: MD Emilio Bertani
#816 Resection at Diagnosis of the Primary Pancreatic Neuroendocrine Tumor in Patients with Unresectable Liver Metastases. A Possible New Approach for a Multimodal Treatment
Introduction: Pancreatic neuroendocrine tumors (PNETs) present in more than 50% of cases with liver metastases as the only systemic localization. Liver metastases are unresectable in 80% of cases at diagnosis. In the context of metastatic disease, the benefit of primary tumor removal in terms of survival is controversial
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: Emilio Bertani
#817 Surgery after Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Introduction: There are a few case reports on surgery after peptide receptor radionuclide therapy (PRRT).
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: Emilio Bertani
Authors: Bertani E, Chiappa A, Fazio N, Grana C, ...
#842 O6-Methylguanine DNA Methyltransferase (MGMT) Expression and Ki-67 Index Predict Response to Temozolomide in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors (WDPNET)
Introduction: Temozolomide (TEM) showed encouraging results in WDPNET. Decreased MGMT expression and methylation of its promoter seems to correlate with better outcome in TEM-treated glioblastomas.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Dr Jerome Cros
Authors: Cros J, Hentic O, Rebours V, Zappa M, ...
#1348 Resectable Primary Tumor in Patients with Pancreatic Neuroendocrine Tumors Located to the Body or Tail and Unresectable Liver Metastases: Does Distal Pancreatectomy Improve Survival?
Introduction: The role of primary tumor surgery in pancreatic neuroendocrine tumor (PNET) with unresectable liver metastases is controversial and international guidelines do not recommend surgery in that setting of patients
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: Dr Emilio Bertani
Authors: Bertani E, Fazio N, Grana C, Chiappa A, ...
#1546 O6-Methylguanine DNA Methyltransferase (MGMT) Expression by Immunochemistry May Help Predict Response to Streptozotocin-based Chemotherapy in Pancreatic Neuroendocrine Tumours
Introduction: Streptozotocin (STZ) is an alkylating agent inducing DNA damage mainly repaired by MGMT. STZ-based chemotherapy is the first line treatment of non-resectable well-differentiated PNET. As for temozolomide, tumour MGMT deficiency may predict the efficacy of STZ in PNET.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Olivia Hentic
Authors: Hentic O, Cros J, Zappa M, Rebours V, ...
Keywords: MGMT, Streptozotocin, PFS
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.